Coronary heart disease, angina pectoris
Conditions
Interventions
Product Name: Trombyl
Pharmaceutical Form: Tablet
Product Name: Plavix
Pharmaceutical Form: Tablet
Sponsors
Per Whiss, Faculty of Health Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consecutive patients, 40-70 years, at the Heartrehabilitation unit, University hospital in Linköping, Sweden which have earlier been diagnosed as instable angina or have been treated with percutaneous coronary intervention (PCI) and are treated with Trombyl + Plavix. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Insulin treated diabetes - Immunological or malignant disease - Acute liver disease or increased liver enzymes in plasma (>20 % of reference) - Renal disease or S-kreatinin >150 umol/L - Heart insufficiency NYHA class III-IV - Hemodynamic important heart valve defect - Treatment with antibiotics, immunosuppressive, including corticosteroids, or continous NSAID intake (not ioncluding low dose ASA) - Thoracal epidural anesthesia caused by severe angina
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate if novel platelet assays could be used to monitor therapeutic effects of antiplatelet agents.;Secondary Objective: ;Primary end point(s): Last visit of the last subject undergoing the trial | — |
Countries
Sweden
Outcome results
None listed